Cantor Fitzgerald Reiterates “Overweight” Rating for Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences (NASDAQ:APTOGet Rating) (TSE:APS)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday, reports. Cantor Fitzgerald also issued estimates for Aptose Biosciences’ FY2022 earnings at ($0.45) EPS and FY2023 earnings at ($0.42) EPS.

Separately, assumed coverage on Aptose Biosciences in a research note on Monday. They issued a “hold” rating on the stock.

Aptose Biosciences Trading Down 4.9 %

Shares of APTO opened at $0.61 on Wednesday. The company has a market capitalization of $55.83 million, a PE ratio of -0.96 and a beta of 1.48. Aptose Biosciences has a 12 month low of $0.58 and a 12 month high of $2.78. The stock’s 50-day moving average price is $0.78 and its two-hundred day moving average price is $0.96.

Aptose Biosciences (NASDAQ:APTOGet Rating) (TSE:APS) last announced its quarterly earnings data on Tuesday, August 2nd. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Equities research analysts predict that Aptose Biosciences will post -0.49 EPS for the current fiscal year.

Institutional Trading of Aptose Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Gleason Group Inc. bought a new stake in Aptose Biosciences in the 1st quarter valued at about $25,000. Sequoia Financial Advisors LLC bought a new stake in Aptose Biosciences in the 1st quarter valued at about $27,000. Rockefeller Capital Management L.P. increased its position in Aptose Biosciences by 1,334.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 21,809 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 20,289 shares in the last quarter. Bayesian Capital Management LP bought a new stake in Aptose Biosciences in the 4th quarter valued at about $51,000. Finally, Toronto Dominion Bank increased its holdings in Aptose Biosciences by 76.6% during the 1st quarter. Toronto Dominion Bank now owns 50,186 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 21,776 shares in the last quarter. 27.16% of the stock is owned by institutional investors.

About Aptose Biosciences

(Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

See Also

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with's FREE daily email newsletter.